Suvratoxumab

Summary

Suvratoxumab (CHEMBL3989997) is a phase-3 clinical-stage antibody; indicated across 2 conditions including staphylococcal pneumonia and staphylococcus aureus infection.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 2 conditions
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3989997
Name	Suvratoxumab
Type	Antibody
Max phase	3

Also known as: MEDI-4893, MEDI4893, Suvratoxumab, SUVRATOXUMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
staphylococcal pneumonia	2	MONDO:0005970	MONDO:0041879
staphylococcus aureus infection	1	MONDO:0005545	EFO:0005681

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05331885	PHASE3	TERMINATED	A Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects - 2
NCT02296320	PHASE2	COMPLETED	Study of the Efficacy and Safety of MEDI4893
NCT01769417	PHASE1	COMPLETED	A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI4893 in Healthy Adult Subjects

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).